Trump CMS resists bipartisan Medicare plan
A bipartisan group of over 50 lawmakers is urging the CMS to remove a proposed fixed-dose combination policy from its final rule implementing Medicare's drug price negotiation program. They argue the policy would force some new and improved drug treatments to face negotiations too soon after FDA approval, potentially discouraging innovation and limiting patient access to advanced therapies, especially in cancer treatment. The lawmakers emphasize that recent therapeutic improvements are evaluated separately by the FDA and should be treated as distinct medicines under Medicare.
articleDetails.fontSize.sizeحجم النص
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading